// App-Quantinova.ai

663 : Biology and Outcome of 85 Adults with Acute Lymphoblastic Leukemia (ALL) with t(4;11)/MLL-AF4 Treated in the UKALL XII/ECOG 2993 Study

Researchers

Presenter

  • Anthony V Moorman

Principal Investigators

  • Lucy Chilton

  • Martin S Tallman

  • Hillard M. Lazarus

  • Elisabeth Paietta

  • Gordon de Wald

  • Adele K Fielding

  • Anthony H. Goldstone

  • Mark R Litzow

  • Selina M. Luger

  • Andrew McMillan

  • Jacob M. Rowe

Medical Centers

  • Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom

  • Northern Institute for Cancer Research Newcastle University, Newcastle, United Kingdom

  • Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Technion-Israel Institute of Technology, Haifa, Israel

  • Academic Department of Haematology, Hampstead Campus, University College London, London, United Kingdom

  • Molecular and Cellular Medicine, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom

  • Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom

Locations

  • United Kingdom

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 105 Antigen

  • Cluster of Differentiation 34

  • Prominin 1

  • Cyclin Dependent Kinase Inhibitor 2A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved